Headline: FDA oncology advisory panel votes 6–3 against camizestrant after SERENA‑6 review Key points - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6–3 against approving AstraZeneca’s oral SERD camizestrant following review of the phase 3 SERENA‑6 trial. - Panel members concluded the trial did not demonstrate a “clinically meaningful” benefit and raised concerns about the overall data package and the sponsor’s characterization of the agent as a “new paradigm.” - SERENA‑6 targeted ESR1‑mutated, HR /HER2− breast cancer — a high‑interest molecular subgroup in modern breast oncology. - The meeting was the FDA’s first oncology advisory session in about nine months and focused in part on AstraZeneca programs. - Several practicing oncologists and academic physicians described the 6–3 vote as a meaningful negative signal, though ODAC recommendations are advisory and do not automatically determine the FDA’s final decision. Implications - The negative ODAC recommendation increases regulatory and commercial uncertainty for AstraZeneca’s camizestrant and its broader oral SERD program, complicating the path forward for approval and adoption. Sources: coverage of the ODAC meeting and reactions to the SERENA‑6 results.